Mission Statement:
The purpose of the Musculoskeletal Tumor Registry is to improve the care, outcomes, and overall quality of life for patients with sarcomas and other rare and aggressive tumors of the musculoskeletal system.
Strategy:
We will improve care, outcomes, and quality of life for patients with musculoskeletal tumors through development of a first-in-kind centralized record of patient, tumor, treatment, and outcomes data on musculoskeletal neoplasia in the pelvis, spine, and extremities. The data will be of research quality and allow for investigation into the natural history of disease, risk factors, quality and delivery of care, oncologic and reconstructive outcomes, prognosis, function, and patient quality-of-life. Database design should facilitate maximum participation by AAOS and MSTS members with clear goals to minimize the burden of data entry, capture a comprehensive set of relevant information, and to maintain flexibility for future modification as needed.
Charges:
- Align all activities to support execution and achievement of the mission, vision, goals, strategic objectives and metrics of the Strategic Plan and conduct all business in accordance with the Core Values as adopted by the Board of Directors.
- Establish a comprehensive infrastructure and standardized system for collecting patient, tumor, treatment, and outcomes data on musculoskeletal neoplasia across the United States.
- Enable research into the natural history, risk factors, quality and delivery of care, oncologic and reconstructive outcomes, prognosis, function, and patient quality-of-life for musculoskeletal neoplasia.
- Facilitate maximum participation from AAOS and MSTS members by minimizing data entry burden while capturing a comprehensive set of relevant information.
- Maintain flexibility to modify and adapt the registry as needed to address evolving research needs and priorities in musculoskeletal oncology.
- Leverage the collected data to identify gaps in knowledge, inform practice guidelines, and define quality measures for musculoskeletal oncology care.
- Promote patient safety and reduce morbidity and mortality associated with musculoskeletal neoplasia through improved understanding, early detection, and optimized treatment strategies.
- Enable longitudinal tracking of patient-reported outcomes, including quality of life measures, to better understand the long-term impact of musculoskeletal neoplasia and its treatment on patient well-being.
Composition:
- CHAIR (1)
- MEMBER-AT-LARGE (9)
Terms:
- For members, three (3) years; eligible for one (1) additional three (3) year term.
- Chair can serve three (3) years; eligible for one (1) additional three (3) year term.